These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 18537151)

  • 21. [Expressions of inducible nitric oxide synthase and vascular endothelial growth factor and their relationship with microvessel density in hepatocellular carcinoma].
    Xiao G; Zhang WM; Zhang M; Xie D; Guo AL; Wen JM
    Ai Zheng; 2005 Jan; 24(1):99-103. PubMed ID: 15642211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
    Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
    Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
    Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
    Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
    Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST
    Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.
    Pan HW; Ou YH; Peng SY; Liu SH; Lai PL; Lee PH; Sheu JC; Chen CL; Hsu HC
    Cancer; 2003 Jul; 98(1):119-27. PubMed ID: 12833464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis.
    Fujii T; Nomoto S; Koshikawa K; Yatabe Y; Teshigawara O; Mori T; Inoue S; Takeda S; Nakao A
    Hepatology; 2006 Jun; 43(6):1267-75. PubMed ID: 16628605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
    Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
    Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
    Tseng PL; Tai MH; Huang CC; Wang CC; Lin JW; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
    J Surg Oncol; 2008 Oct; 98(5):349-57. PubMed ID: 18646041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma.
    Stroescu C; Dragnea A; Ivanov B; Pechianu C; Herlea V; Sgarbura O; Popescu A; Popescu I
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):411-7. PubMed ID: 19104702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma.
    Zhang HK; Pan K; Wang H; Weng DS; Song HF; Zhou J; Huang W; Li JJ; Chen MS; Xia JC
    Cancer Lett; 2008 Mar; 261(2):183-92. PubMed ID: 18160212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.
    Fang F; Luo LB; Tao YM; Wu F; Yang LY
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):409-16. PubMed ID: 19208663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma.
    Liu AW; Cai J; Zhao XL; Xu AM; Fu HQ; Nian H; Zhang SH
    J Clin Pathol; 2009 Nov; 62(11):1003-8. PubMed ID: 19861558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor.
    Tsunedomi R; Iizuka N; Tamesa T; Sakamoto K; Hamaguchi T; Somura H; Yamada M; Oka M
    Clin Cancer Res; 2008 Feb; 14(4):1025-31. PubMed ID: 18281534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma.
    Chau GY; Lee AF; Tsay SH; Ke YR; Kao HL; Wong FH; Tsou AP; Chau YP
    Histopathology; 2007 Aug; 51(2):204-18. PubMed ID: 17559540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma.
    Yamaguchi R; Yano H; Nakashima O; Akiba J; Nishida N; Kurogi M; Kojiro M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):152-60. PubMed ID: 16706827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma.
    Iavarone M; Lampertico P; Iannuzzi F; Manenti E; Donato MF; Arosio E; Bertolini F; Primignani M; Sangiovanni A; Colombo M
    J Viral Hepat; 2007 Feb; 14(2):133-9. PubMed ID: 17244253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression and clinical impact of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma].
    Guo RP; Zhong C; Shi M; Zhang CQ; Wei W; Zhang YQ; Li JQ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):285-8. PubMed ID: 16875630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical values of vascular endothelial growth factor expression and microvascular density analysis in liver cancer specimens].
    Yao DF; Zhu Y; Wu XH; Wu W; Qiu LW
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):92-4. PubMed ID: 14980110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the midkine gene in human hepatocellular carcinomas.
    Koide N; Hada H; Shinji T; Ujike K; Hirasaki S; Yumoto Y; Hanafusa T; Kadomatsu K; Muramatsu H; Muramatsu T; Tsuji T
    Hepatogastroenterology; 1999; 46(30):3189-96. PubMed ID: 10626184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
    Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.